Hennion & Walsh Asset Management Inc. Buys 127,644 Shares of Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. lifted its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 32.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 519,120 shares of the company’s stock after buying an additional 127,644 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Taysha Gene Therapies were worth $3,535,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after acquiring an additional 82,545 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Taysha Gene Therapies by 13.5% during the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares in the last quarter. Prudential Financial Inc. lifted its position in shares of Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after purchasing an additional 7,650 shares in the last quarter. Invesco Ltd. boosted its holdings in Taysha Gene Therapies by 27.4% during the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock worth $470,000 after purchasing an additional 43,772 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Taysha Gene Therapies in the 2nd quarter worth about $184,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $6.37 on Tuesday. The stock’s 50-day moving average is $6.06 and its 200 day moving average is $5.45. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -16.76 and a beta of 1.22. Taysha Gene Therapies, Inc. has a 1-year low of $2.68 and a 1-year high of $7.30. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TSHA has been the subject of several analyst reports. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Robert W. Baird raised their price objective on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. The Goldman Sachs Group lifted their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Bank of America upped their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average target price of $12.77.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.